Assays for Modulators of Ryanodine Receptor (RyR)/Ca2+ Release Channel Activity for Drug Discovery for Skeletal Muscle and Heart Diseases.

Q2 Pharmacology, Toxicology and Pharmaceutics
Takashi Murayama, Nagomi Kurebayashi
{"title":"Assays for Modulators of Ryanodine Receptor (RyR)/Ca<sup>2+</sup> Release Channel Activity for Drug Discovery for Skeletal Muscle and Heart Diseases.","authors":"Takashi Murayama,&nbsp;Nagomi Kurebayashi","doi":"10.1002/cpph.71","DOIUrl":null,"url":null,"abstract":"<p><p>The ryanodine receptor (RyR) is a Ca<sup>2+</sup> release channel that is present in the sarcoplasmic reticulum and endoplasmic reticulum (ER) and that plays a central role in excitation-contraction coupling in skeletal and cardiac muscle. Hyperactivation of RyR by genetic mutations or posttranslational modification can cause various skeletal muscle and arrhythmogenic heart diseases. Inhibitors of RyR are therefore expected to be potential drugs for treatment of such diseases. This article describes assays to evaluate RyR channel activity, including an ER Ca<sup>2+</sup> measurement assay that is compatible with high-throughput screening and a [<sup>3</sup> H]-ryanodine binding assay that provides a quantitative measure of RyR channel activity as a second screen for compound hits. © 2019 by John Wiley & Sons, Inc. Basic Protocol 1: [Ca<sup>2+</sup> ]<sub>ER</sub> assay for ryanodine receptor (RyR) channel activity Support Protocol 1: Determination of dose dependence and isoform selectivity of RyR inhibitors using [Ca<sup>2+</sup> ]<sub>ER</sub> assay Basic Protocol 2: [<sup>3</sup> H]-Ryanodine binding assay for RyR channel activity Support Protocol 2: Isolation of microsomes from RyR-expressing HEK293 cells.</p>","PeriodicalId":10871,"journal":{"name":"Current Protocols in Pharmacology","volume":"87 1","pages":"e71"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpph.71","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/cpph.71","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 15

Abstract

The ryanodine receptor (RyR) is a Ca2+ release channel that is present in the sarcoplasmic reticulum and endoplasmic reticulum (ER) and that plays a central role in excitation-contraction coupling in skeletal and cardiac muscle. Hyperactivation of RyR by genetic mutations or posttranslational modification can cause various skeletal muscle and arrhythmogenic heart diseases. Inhibitors of RyR are therefore expected to be potential drugs for treatment of such diseases. This article describes assays to evaluate RyR channel activity, including an ER Ca2+ measurement assay that is compatible with high-throughput screening and a [3 H]-ryanodine binding assay that provides a quantitative measure of RyR channel activity as a second screen for compound hits. © 2019 by John Wiley & Sons, Inc. Basic Protocol 1: [Ca2+ ]ER assay for ryanodine receptor (RyR) channel activity Support Protocol 1: Determination of dose dependence and isoform selectivity of RyR inhibitors using [Ca2+ ]ER assay Basic Protocol 2: [3 H]-Ryanodine binding assay for RyR channel activity Support Protocol 2: Isolation of microsomes from RyR-expressing HEK293 cells.

Ryanodine受体(RyR)/Ca2+释放通道活性调节剂用于骨骼肌和心脏病药物发现的测定。
ryanodine受体(RyR)是一种Ca2+释放通道,存在于肌浆网和内质网(ER)中,在骨骼肌和心肌的兴奋-收缩偶联中起核心作用。基因突变或翻译后修饰导致RyR过度激活可引起各种骨骼肌和心律失常性心脏病。因此,RyR抑制剂有望成为治疗此类疾病的潜在药物。本文描述了评估RyR通道活性的方法,包括与高通量筛选兼容的ER Ca2+测量方法和[3h]-ryanodine结合方法,该方法提供了RyR通道活性的定量测量,作为化合物碰撞的第二筛选方法。©2019 by John Wiley & Sons, Inc。基本方案1:[Ca2+]ER测定RyR受体(RyR)通道活性支持方案1:使用[Ca2+]ER测定RyR抑制剂的剂量依赖性和异构体选择性基本方案2:[3h]-Ryanodine结合测定RyR通道活性支持方案2:从表达RyR的HEK293细胞中分离微粒体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Protocols in Pharmacology
Current Protocols in Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信